KINTARA THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.1488 USD | -5.82% |
|
+22.57% | -12.26% |
| Apr. 03 | Sector Update: Health Care Stocks Softer Late Afternoon | MT |
| Apr. 03 | Sector Update: Health Care | MT |
Valuation
| Fiscal Period: June | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 15.03 | 4.937 | 7.864 | 74.04 | 18.22 | 6.819 |
| Enterprise Value (EV) 1 | 9.062 | 1.218 | 5.471 | 63.01 | 6.438 | 4.209 |
| P/E ratio | -1.26 x | -0.41 x | -0.79 x | -1.42 x | -0.54 x | -0.43 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | - | - |
| EV / Revenue | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | -2,924,781 x | -284,595 x | -285,659 x |
| EV / FCF | -1.59 x | -0.4 x | -1.39 x | -8.09 x | -0.57 x | -0.54 x |
| FCF Yield | -62.7% | -250% | -71.8% | -12.4% | -176% | -186% |
| Price to Book | -792 x | -82.3 x | -86.8 x | -17.1 x | -24 x | -0.69 x |
| Nbr of stocks (in thousands) | 2,201 | 3,827 | 11,433 | 652 | 1,311 | 1,692 |
| Reference price 2 | 341.5 | 64.50 | 34.39 | 113.5 | 13.90 | 4.030 |
| Announcement Date | 9/24/18 | 9/9/19 | 9/18/20 | 9/28/21 | 9/27/22 | 9/18/23 |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: June | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales | - | - | - | - | - | - |
| EBITDA | - | - | - | -21.54 | -22.62 | -14.74 |
| EBIT 1 | -11.17 | -8.398 | -8.145 | -21.57 | -22.68 | -14.8 |
| Operating Margin | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -11.14 | -8.048 | -9.126 | -38.3 | -22.66 | -14.65 |
| Net income 1 | -11.14 | -8.048 | -9.126 | -38.3 | -22.66 | -14.65 |
| Net margin | - | - | - | - | - | - |
| EPS 2 | -271.2 | -157.9 | -43.73 | -80.17 | -25.80 | -9.271 |
| Free Cash Flow 1 | -5.682 | -3.044 | -3.926 | -7.786 | -11.35 | -7.82 |
| FCF margin | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 9/24/18 | 9/9/19 | 9/18/20 | 9/28/21 | 9/27/22 | 9/18/23 |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: Juni | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - |
| EBIT | -5.971 | -5.895 | -5.358 | - | -3.499 | - | -3.349 | - |
| Operating Margin | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) | -5.966 | -5.893 | -5.356 | - | -3.454 | - | -3.335 | - |
| Net income | -8.43 | -5.895 | -5.358 | -4.596 | -3.454 | -3.264 | -3.337 | - |
| Net margin | - | - | - | - | - | - | - | - |
| EPS | -12.50 | -6.000 | -5.500 | -3.500 | -2.100 | -1.940 | -1.950 | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 11/15/21 | 2/11/22 | 5/13/22 | 11/9/22 | 2/14/23 | 5/11/23 | 9/18/23 | - |
1USD in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: Juni | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 5.97 | 3.72 | 2.39 | 11 | 11.8 | 2.61 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | -5.68 | -3.04 | -3.93 | -7.79 | -11.3 | -7.82 |
| ROE (net income / shareholders' equity) | -185% | -217% | -818% | -706% | -203% | -234% |
| ROA (Net income/ Total Assets) | -93.2% | -94.5% | -146% | -164% | -96.1% | -92.8% |
| Assets 1 | 11.95 | 8.519 | 6.253 | 23.41 | 23.57 | 15.78 |
| Book Value Per Share 2 | -0.4300 | -0.7800 | -0.4000 | -6.640 | -0.5800 | -5.860 |
| Cash Flow per Share 2 | 2.600 | 0.9700 | 0.2100 | 16.10 | 8.990 | 0.9100 |
| Capex | - | - | - | 0.01 | - | 0.23 |
| Capex / Sales | - | - | - | - | - | - |
| Announcement Date | 9/24/18 | 9/9/19 | 9/18/20 | 9/28/21 | 9/27/22 | 9/18/23 |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -12.26% | 8.23M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- KTRA Stock
- Financials Kintara Therapeutics, Inc.
